Title:
ENGINEERED IMMUNE EFFECTOR CELL AND COMPOSITION AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2024/067682
Kind Code:
A1
Abstract:
The present application relates to a genetically modified immune cell for expressing a recombinant human CD16 protein. The recombinant human CD16 protein has additions, deletions and replacements of, or any combination of the additions, deletions and replacements of one or more amino acids as compared to a wild-type amino acid sequence, and has enhanced shear resistance.
Inventors:
JIANG FUWEI (CN)
LIU TINGTING (CN)
WANG YIFANG (CN)
YANG CUIQING (CN)
CAO ZHUOXIAO (CN)
LIU TINGTING (CN)
WANG YIFANG (CN)
YANG CUIQING (CN)
CAO ZHUOXIAO (CN)
Application Number:
PCT/CN2023/121947
Publication Date:
April 04, 2024
Filing Date:
September 27, 2023
Export Citation:
Assignee:
SHANGHAI SIMNOVA BIOTECHNOLOGY CO LTD (CN)
International Classes:
C12N5/10; A61K38/17; C07K14/735
Domestic Patent References:
| WO2019163919A1 | 2019-08-29 |
Foreign References:
| CN113699159A | 2021-11-26 | |||
| CN106715467A | 2017-05-24 | |||
| CN111542594A | 2020-08-14 | |||
| CN114478806A | 2022-05-13 |
Other References:
RATAJ FELICITAS; JACOBI SEVERIN J.; STOIBER STEFAN; ASANG FLORIAN; OGONEK JUSTYNA; TOKAREW NICHOLAS; CADILHA BRUNO L.; VAN PUIJENB: "High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy", BRITISH JOURNAL OF CANCER, vol. 120, no. 1, 15 November 2018 (2018-11-15), London, pages 79 - 87, XP036927740, ISSN: 0007-0920, DOI: 10.1038/s41416-018-0341-1
Attorney, Agent or Firm:
INSIGHT INTELLECTUAL PROPERTY LTD. (CN)
Download PDF:
Previous Patent: MOWER AND MOWER START AND STOP CONTROL METHOD
Next Patent: CELL SELECTION AND/OR RESELECTION METHOD AND DEVICE
Next Patent: CELL SELECTION AND/OR RESELECTION METHOD AND DEVICE